Mark Alan Goldberg insider trades
Open-market stock purchases and sales by Mark Alan Goldberg, Director at Blueprint Medicines Corp, from SEC Form 4 filings since Dec 20, 2011.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +116%.
Recent trades
No open-market trades in the last 12 months.
Companies traded
- BPMC Blueprint Medicines Corp: 1 buy, 6 sales, last Jul 17, 2025
- GLYC Glycomimetics Inc: 1 buy, last May 1, 2024
- IMGN ImmunoGen, Inc: 3 buys, last Feb 12, 2024
- IDRA Idera Pharmaceuticals, Inc: 1 buy, last Jun 23, 2022
- BOLD Audentes Therapeutics, Inc: other filings, last Jan 15, 2020
- LIFE aTYR PHARMA Inc: other filings, last May 9, 2017
- GEVA Synageva Biopharma Corp: 18 sales, last Sep 19, 2014